Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020
April 30 2020 - 4:05PM
Business Wire
Conference Call Scheduled for Thursday, May 7,
2020 at 4:30 p.m. ET
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company focused on innovative aesthetic and therapeutic offerings,
including its next-generation neuromodulator product,
DaxibotulinumtoxinA for Injection, today announced that the company
will release first quarter 2020 financial results on Thursday, May
7, 2020 after the close of market. Revance will host a
corresponding conference call and a live webcast at 1:30 p.m.
PT/4:30 p.m. ET on the same day to discuss the results and provide
a business and pipeline update.
Individuals interested in listening to the conference call may
do so by dialing (855) 453-3827 for domestic callers, or (484)
756-4301 for international callers and reference conference ID:
4799936; or from the webcast link in the investor relations section
of the company’s website at: www.revance.com.
A replay of the call will be available beginning May 7, 2020 at
4:30 p.m. PT/7:30 p.m. ET to May 8, 2020 at 4:30 p.m. PT/7:30 p.m.
ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and
reference conference ID: 4799936. The live webcast can be access
here and will be available in the investor relations section on the
company's website for 30 days following the completion of the
call.
In light of reduced call center resources during this time of
required social-distancing, Revance requests listeners not planning
on participating in Q&A to listen to the live webcast rather
than dialing in by phone.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on
innovative aesthetic and therapeutic offerings, including its
next-generation neuromodulator product, DaxibotulinumtoxinA for
Injection. DaxibotulinumtoxinA for Injection combines a proprietary
stabilizing peptide excipient with a highly purified botulinum
toxin that does not contain human or animal-based components.
Revance has successfully completed a Phase 3 program for
DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is
pursuing U.S. regulatory approval in 2020. Revance is also
evaluating DaxibotulinumtoxinA for Injection in the full upper
face, including glabellar lines, forehead lines and crow’s feet, as
well as in three therapeutic indications - cervical dystonia, adult
upper limb spasticity and plantar fasciitis. Beyond
DaxibotulinumtoxinA for Injection, Revance gained exclusive rights
to commercialize TEOXANE SA’s Resilient Hyaluronic Acid® (RHA®)
line of fillers in the U.S., the first and only range of
FDA-approved dermal fillers for correction of dynamic facial
wrinkles and folds. Revance has also begun development of a
biosimilar to BOTOX®, which would compete in the existing
short-acting neuromodulator marketplace. Revance is dedicated to
making a difference by transforming patient experiences. For more
information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid®
and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered
trademark of Allergan, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200430005843/en/
Investors Revance Therapeutics, Inc.: Jeanie Herbert,
714-325-3584 jherbert@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476
sfahy@revance.com or General Media: Y&R: Jenifer Slaw,
347-971-0906 jenifer.slaw@YR.com or Trade Media: Nadine Tosk,
504-453-8344 nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024